Patients
SOLID TUMOR
Eligible male or female Japanese patients ≥20 years of age were enrolled in the study. Part 1 enrolled patients with any histologically confirmed, measurable advanced solid tumor malignancy; Part 2 enrolled patients with any histologically confirmed, measurable advanced solid tumor malignancy and any documented Patients were excluded from the study if they had received: a selective FGFR inhibitor ever, any anticancer medications or any other investigational drug within 21 days or 5 half‐lives (whichever is longer; 6 weeks for mitomycin‐C or nitrosoureas, 7 days for tyrosine kinase inhibitors), any potent 